2QK Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.20 |
| 52 Week High | US$31.80 |
| 52 Week Low | US$6.15 |
| Beta | 0.48 |
| 11 Month Change | -5.26% |
| 3 Month Change | 215.00% |
| 1 Year Change | 142.31% |
| 33 Year Change | 15.60% |
| 5 Year Change | 213.04% |
| Change since IPO | 168.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | 142.3% | -17.2% | 8.2% |
Return vs Industry: 2QK exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 2QK exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 2QK volatility | |
|---|---|
| 2QK Average Weekly Movement | 99.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2QK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2QK's weekly volatility has increased from 51% to 99% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 150 | Jay Backstrom | scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation Fundamentals Summary
| 2QK fundamental statistics | |
|---|---|
| Market cap | €2.69b |
| Earnings (TTM) | -€217.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.4x
P/E RatioIs 2QK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$169.15m |
| Gross Profit | -US$169.15m |
| Other Expenses | US$56.82m |
| Earnings | -US$225.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 63.3% |
How did 2QK perform over the long term?
See historical performance and comparison